Silence gets more US patnets
October 18, 2017Silence Therapeutics got the US Patent and Trade Mark Office on Tuesday, after previously reporting issuance of a notice of allowance for US patent application on August 15, 2017 and for US patent application on September 11, 2017.
The allowed claims of the two US Patents will provide Silence with further protection for its innovative chemical modification technology in the US. Silence believes that these newly granted claims are relevant to third-party RNAi medicines, including Alnylam Pharmaceuticals’ products such as Patisiran, Fitusiran, Inclisiran, Givosiran and Cemdisiran.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, said that the grants provide further protection for its US patent estate. The company has now been granted ten US patents, one US patent application, three granted European patents and four European patent applications encompassing our chemical modification technology. He said that the company’s chemical modification patent portfolio also encompasses patents and patent applications in Australia, Brazil, Canada, China, Israel, India, Japan, Korea, Mexico and South Africa.
“We continue to believe that several third party late-stage RNAi candidates require licences under our chemical modification patent portfolio. This includes Alnylam Pharmaceuticals’ products such as Patisiran, Fitusiran, Inclisiran, Givosiran and Cemdisiran,” Mortazavi said.
